Predictors of Benefit in Colorectal Cancer Treated With Cetuximab: Are We Getting "Lost in TranslationAL"? Reply

Jacobs, Bart; Piessevaux, Hubert; De Roock, Wendy; Biesmans, Bart; De Schutter, Jef; Claes, Bart; Tejpar, Sabine

doi:10.1200/JCO0.2009.26.6809

Predictors of Benefit in Colorectal Cancer Treated With Cetuximab: Are We Getting "Lost in TranslationAL"? Reply

Jacobs, Bart

;

Piessevaux, Hubert

;

De Roock, Wendy

;

Biesmans, Bart

;

Tejpar, Sabine

;et.al.

(2010) Journal of Clinical Oncology — Vol. 28, n° 11, p. E175-E176 (2010)

Files

No attached file found for this publication.

Details

Authors

Jacobs, BartUCLouvain
Author
Piessevaux, HubertUCLouvain
Author
De Roock, WendyUCLouvain
Author
Biesmans, BartUCLouvain
Author
De Schutter, JefUCLouvain
Author
Claes, BartUCLouvain
Author
Tejpar, SabineUCLouvain
Author

Affiliations

UCLouvainCliniques universitaires Saint-Luc
UCLouvainSSS/IREC - Institut de recherche expérimentale et clinique

Citations

APA
Chicago
FWB

Jacobs, B., Piessevaux, H., De Roock, W., Biesmans, B., De Schutter, J., Claes, B., & Tejpar, S. (2010). Predictors of Benefit in Colorectal Cancer Treated With Cetuximab: Are We Getting “Lost in TranslationAL”? Reply. Journal of Clinical Oncology, 28(11), E175-E176. https://doi.org/10.1200/JCO0.2009.26.6809 (Original work published 2010)